UB Paderborn / Katalog / Suche / in CDI

A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs

Blood, 2021-11, Vol.138 (21), p.2031-2041

2021

Volltextzugriff (PDF)

A Prospective Long-term Study of 220 Patients With a Retrievable Vena Cava Filter for Secondary Prevention of Venous Thromboembolism

Chest, 2007-01, Vol.131 (1), p.223-229

2007

Volltextzugriff (PDF)

Compliance and stability of INR of two oral anticoagulants with different half-lives: a randomised trial

Thrombosis and haemostasis, 2003-03, Vol.89 (3), p.458

2003

Volltextzugriff (PDF)

Phase 2 study of nilotinib in pediatric patients with Philadelphia chromosome–positive chronic myeloid leukemia

Blood, 2019-12, Vol.134 (23), p.2036-2045

2019

Volltextzugriff (PDF)

Efficacy and safety results from ASCEMBL, a phase 3 study of asciminib versus bosutinib (BOS) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after ≥2 prior tyrosine kinase inhibitors (TKIs): Week 96 update

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.7004-7004

2022

Volltextzugriff (PDF)

Optimal low-molecular-weight heparin regimen in major orthopaedic surgery. A meta-analysis of randomised trials

Thrombosis and haemostasis, 2003-10, Vol.90 (4), p.654

2003

Volltextzugriff (PDF)

Enoxaparin in the Treatment of Deep Vein Thrombosis With or Without Pulmonary Embolism

Chest, 2005-10, Vol.128 (4), p.2203-2210

2005

Volltextzugriff (PDF)

Asciminib (ABL001) in Combination with Imatinib in Patients with Chronic Myeloid Leukemia in Chronic Phase Who Have Not Achieved a Deep Molecular Response with Long-Term Frontline Imatinib: A Randomized, Open-Label, Multicenter, Phase 2 Study

Clinical lymphoma, myeloma and leukemia, 2018-09, Vol.18, p.S222-S223

2018

Volltextzugriff (PDF)

Enoxaparin in the treatment of deep vein thrombosis with or without pulmonary embolism : An individual patient data meta-analysis

Chest, 2005-10, Vol.128 (4), p.2203-2210

2005

Volltextzugriff (PDF)

Factors predictive of venous thrombotic complications in patients with isolated superficial vein thrombosis

Journal of vascular surgery, 2003-11, Vol.38 (5), p.944-949

2003

Volltextzugriff (PDF)

Brain magnetic resonance imaging findings in cryptogenic stroke patients under 60 years with patent foramen ovale

European journal of radiology, 2014-05, Vol.83 (5), p.824-828

2014

Volltextzugriff (PDF)

Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assays. A multicentre French GEHT study

Thrombosis and haemostasis, 2014-02, Vol.111 (2), p.240

2014

Volltextzugriff (PDF)

Superficial vein thrombosis: risk factors, diagnosis, and treatment

Current opinion in pulmonary medicine, 2003-09, Vol.9 (5), p.393-397

2003

Volltextzugriff (PDF)

Thrombophilia and risk of venous thrombosis in patients with cancer

Thrombosis research, 2007, Vol.120 (4), p.S51-S61

2007

Volltextzugriff (PDF)

Pulmonary embolism and 3-month outcomes in 4036 patients with venous thromboembolism and chronic obstructive pulmonary disease: data from the RIETE Registry

Respiratory research, 2013-07

2013

Volltextzugriff (PDF)

Feasibility of an easy-to-use risk score in the prevention of venous thromboembolism and placental vascular complications in pregnant women: A prospective cohort of 2736 women

Thrombosis research, 2008, Vol.122 (4), p.478-484

2008

Volltextzugriff (PDF)

Easy-to-use risk score in prevention of venous thromboembolism and placental vascular complications in pregnant women: Response from Authors

Thrombosis research, 2008, Vol.122 (5), p.717-718

2008

Volltextzugriff (PDF)

The location of deep-vein thrombosis as a predictive factor for recurrence and cancer discovery after proximal deep-vein thrombosis

Haematologica (Roma), 2003-03, Vol.88 (3), p.ELT08

2003

Volltextzugriff (PDF)

Les statistiques descriptives de base: Méthodologie des essais cliniques

Médecine thérapeutique : MT, 2007, Vol.13 (4), p.255-261

2007

Volltextzugriff (PDF)

Fiche statistique n° I : les statistiques descriptives de base

Médecine thérapeutique : MT, 2004-05, Vol.10 (3), p.187-190

2004

Volltextzugriff (PDF)

Intervalle de confiance: Méthodologie des essais cliniques

Médecine thérapeutique : MT, 2007, Vol.13 (4), p.270-273

2007

Volltextzugriff (PDF)

La randomisation: Méthodologie des essais cliniques

Médecine thérapeutique : MT, 2007, Vol.13 (4), p.250-254

2007

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs

A Prospective Long-term Study of 220 Patients With a Retrievable Vena Cava Filter for Secondary Prevention of Venous Thromboembolism

Compliance and stability of INR of two oral anticoagulants with different half-lives: a randomised trial

Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL

Phase 2 study of nilotinib in pediatric patients with Philadelphia chromosome–positive chronic myeloid leukemia

Efficacy and safety results from ASCEMBL, a phase 3 study of asciminib versus bosutinib (BOS) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after ≥2 prior tyrosine kinase inhibitors (TKIs): Week 96 update

Optimal low-molecular-weight heparin regimen in major orthopaedic surgery. A meta-analysis of randomised trials

Enoxaparin in the Treatment of Deep Vein Thrombosis With or Without Pulmonary Embolism

CML-395 Efficacy and Safety Results From ASCEMBL, a Phase III Study of Asciminib vs. Bosutinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After ≥2 Prior Tyrosine Kinase Inhibitors (TKIs): Week 96 Update

Poster: CML-395 Efficacy and Safety Results From ASCEMBL, a Phase III Study of Asciminib vs. Bosutinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After ≥2 Prior Tyrosine Kinase Inhibitors (TKIs): Week 96 Update

Asciminib (ABL001) in Combination with Imatinib in Patients with Chronic Myeloid Leukemia in Chronic Phase Who Have Not Achieved a Deep Molecular Response with Long-Term Frontline Imatinib: A Randomized, Open-Label, Multicenter, Phase 2 Study

Enoxaparin in the treatment of deep vein thrombosis with or without pulmonary embolism : An individual patient data meta-analysis

Factors predictive of venous thrombotic complications in patients with isolated superficial vein thrombosis

Brain magnetic resonance imaging findings in cryptogenic stroke patients under 60 years with patent foramen ovale

Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assays. A multicentre French GEHT study

Superficial vein thrombosis: risk factors, diagnosis, and treatment

Thrombophilia and risk of venous thrombosis in patients with cancer

Pulmonary embolism and 3-month outcomes in 4036 patients with venous thromboembolism and chronic obstructive pulmonary disease: data from the RIETE Registry

Feasibility of an easy-to-use risk score in the prevention of venous thromboembolism and placental vascular complications in pregnant women: A prospective cohort of 2736 women

Easy-to-use risk score in prevention of venous thromboembolism and placental vascular complications in pregnant women: Response from Authors

The location of deep-vein thrombosis as a predictive factor for recurrence and cancer discovery after proximal deep-vein thrombosis

Les statistiques descriptives de base: Méthodologie des essais cliniques

Fiche statistique n° I : les statistiques descriptives de base

Intervalle de confiance: Méthodologie des essais cliniques

La randomisation: Méthodologie des essais cliniques

Suchergebnisse filtern